RARE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ultragenyx Pharmaceutical is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who is impatient and wants to act now. The stock is trading below key resistance with a bearish technical setup, no strong proprietary buy signal, and mixed-to-negative analyst sentiment after recent target cuts. The long-term story still has upside if late-stage pipeline catalysts succeed, but based on the current data, this is not a clean entry today.
RARE is in a short-term bearish trend. MACD histogram is negative at -0.396 and still contracting, RSI_6 at 38.637 is weak but not oversold, and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Current pre-market price is 23.66, below the pivot of 24.891 and only modestly above S1 at 22.909, which suggests downside pressure remains. The short-term pattern data also points to weak expected returns over the next week and month.
["No major news in the last week, so there is no immediate event-driven catalyst.", "Analysts still see potential upside from GTX-102 in Angelman syndrome if Phase 3 data is positive.", "Upcoming PDUFAs for DTX401 and UX111 could create monetizable PRVs and support the stock.", "Some firms still maintain Outperform/Buy/Overweight ratings, indicating the long-term pipeline still has believers."]
["Recent analyst target cuts show sentiment has weakened after the setrusumab Phase 3 miss and concerns around ASPIRE enrollment.", "Goldman downgraded the stock to Neutral with a sharp target cut, signaling notable fundamental caution.", "No recent news flow means no near-term catalyst is actively driving buying interest.", "Technical trend is bearish, and price is below the pivot with weak momentum.", "Stock trend estimates point to negative returns over the next week and month."]
No usable latest-quarter financial snapshot was provided due to an error, so a full quarter-by-quarter review is not available. From the analyst commentary, however, the company reiterated FY26 revenue guidance, Crysvita is expected to improve through the year, and profitability is still expected around 2027. That suggests the business has a path toward better fundamentals, but the latest quarter itself cannot be confirmed from the provided data.
Analyst sentiment is mixed but leaning cautious. Positive views remain from Evercore ISI, Guggenheim, Barclays, Morgan Stanley, and JPMorgan, with targets ranging from $33 to $74 and several Buy/Outperform/Overweight ratings. However, recent downward revisions from Evercore, Wedbush, Guggenheim, Barclays, Goldman, and JPMorgan show growing skepticism after clinical setbacks. The pros see asymmetric upside from GTX-102 and pipeline catalysts; the cons focus on trial risk, reduced target prices, and reliance on a few key programs.
